1. A Thyroid Genetic Classifier Correctly Predicts Benign Nodules with Indeterminate Cytology: Two Independent, Multicenter, Prospective Validation Trials
- Author
-
Milagros Bracamonte, Elsa Bruce, Marcela Lagos, Antonieta Solar, Félix Vasquez, Naifa L. Busaidy, Miren Osorio, Augusto León, Hernán Tala, René E Díaz, Luis Marín, Tatiana Arias, John Stewart, Emad Kandil, Giovanna Miranda, Jesús Véliz, Alice Tang, Dina Schachter, Eleonora Horvath, Jiang Wang, José Carlos de Miguel Domínguez, Marcela Henríquez, Carmen Franco, Juan Carlos Roa, Paul H. Graham, Mark Zafereo, Hernán E. González, Nicolás Droppelman, Christina S. Kong, Lisa A. Orloff, Maite Lobos, F. Christopher Holsinger, Natalia Mena, Bryan McIver, Patricia Arroyo, Pedro Pineda, Soledad Loyola, David L. Steward, Nelson Wohllk, Francisco Cruz, Michelle A. Williams, Elizabeth G. Grubbs, Eufrosina Traipe, Sergio Vargas-Salas, and Francisco Medina
- Subjects
Thyroid nodules ,Adult ,Male ,medicine.medical_specialty ,Adolescent ,Endocrinology, Diabetes and Metabolism ,Cytodiagnosis ,Biopsy, Fine-Needle ,Thyroid Gland ,030209 endocrinology & metabolism ,gene classifier ,Sensitivity and Specificity ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Endocrinology ,Cytology ,medicine ,Humans ,Prospective Studies ,Thyroid Neoplasms ,Thyroid Nodule ,indeterminate thyroid cytology ,Aged ,Aged, 80 and over ,business.industry ,Thyroid ,Thyroid Cancer and Nodules ,Middle Aged ,medicine.disease ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Female ,Radiology ,Indeterminate ,business ,Classifier (UML) ,clinical validation - Abstract
Background: Although most thyroid nodules with indeterminate cytology are benign, in most of the world, surgery remains as the most frequent diagnostic approach. We have previously reported a 10-gene thyroid genetic classifier, which accurately predicts benign thyroid nodules. The assay is a prototype diagnostic kit suitable for reference laboratory testing and could potentially avoid unnecessary diagnostic surgery in patients with indeterminate thyroid cytology. Methods: Classifier performance was tested in two independent, ethnically diverse, prospective multicenter trials (TGCT-1/Chile and TGCT-2/USA). A total of 4061 fine-needle aspirations were collected from 15 institutions, of which 897 (22%) were called indeterminate. The clinical site was blind to the classifier score and the clinical laboratory blind to the pathology report. A matched surgical pathology and valid classifier score was available for 270 samples. Results: Cohorts showed significant differences, including (i) clinical site patient source (academic, 43% and 97% for TGCT-1 and -2, respectively); (ii) ethnic diversity, with a greater proportion of the Hispanic population (40% vs. 3%) for TGCT-1 and a greater proportion of African American (11% vs. 0%) and Asian (10% vs. 1%) populations for TGCT-2; and (iii) tumor size (mean of 1.7 and 2.5 cm for TGCT-1 and -2, respectively). Overall, there were no differences in the histopathological profile between cohorts. Forty-one of 155 and 45 of 115 nodules were malignant (cancer prevalence of 26% and 39% for TGCT-1 and -2, respectively). The classifier predicted 37 of 41 and 41 of 45 malignant nodules, yielding a sensitivity of 90% [95% confidence interval; CI 77–97] and 91% [95% CI 79–98] for TGCT-1 and -2, respectively. One hundred one of 114 and 61 of 70 nodules were correctly predicted as benign, yielding a specificity of 89% [95% CI 82–94] and 87% [95% CI 77–94], respectively. The negative predictive values for TGCT-1 and TGCT-2 were 96% and 94%, respectively, whereas the positive predictive values were 74% and 82%, respectively. The overall accuracy for both cohorts was 89%. Conclusions: Clinical validation of the classifier demonstrates equivalent performance in two independent and ethnically diverse cohorts, accurately predicting benign thyroid nodules that can undergo surveillance as an alternative to diagnostic surgery.
- Published
- 2020